What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?

Ajjan R. , Storey RF and Grant P. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-390.

Ferreiro JL , Gómez-Hospital JA and Angiolillo DJ Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7: 251-259.

Alzahrani SH and Ajjan RA Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260-273.

Ferreiro JL , Cequier AR and Angiolillo DJ Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diab Vasc Dis Res 2010; 7: 274-288.

Wiviott SD , Braunwald E. , Angiolillo DJ , et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008; 118: 1626-1636.

James S. , Angiolillo DJ , Cornel JH , et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 29 August epub: http://eurheartj.oxfordjournals.org/content/early/2010/08/27/eurheartj.ehq325.abstract

Appraise Steering Committee Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.

Rocket AF Study Investigators. Rivaroxaban - Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.

The TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in acute coronary syndrome (TRA-CER) trial: study design and rationale. Am Heart J 2009; 158: 327-334.

Chintala M. , Shimizu K. , Ogawa M. , Yamaguchi H. , Doi M. and Jensen P. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008; 108: 433-438.

Chintala M. , Strony J. , Yang B. , Kurowski S. and Li Q. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in Cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010: ATVBAHA.110.203414.